Patent application number | Description | Published |
20080292642 | Crystalline anti-human IL-12 antibodies - The invention relates to batch crystallization methods for crystallizing an anti-hIL-12 antibody that allows the production of the antibody on an industrial scale, antibody crystals obtained according to the methods, compositions containing the crystals, and methods of using the crystals and the compositions. | 11-27-2008 |
20090148513 | Compositions and methods for crystallizing antibodies - The present invention relates to a batch crystallization method for crystallizing anti-human TNFalpha (hTNFalpha) antibody and antibody fragments which allows the production of said antibody on an industrial scale; a method of controlling the size of antibody crystals, for example, crystals of anti-hTNFalpha antibody fragments, compositions containing said crystals as well as methods of use of said crystals and compositions. | 06-11-2009 |
20090155346 | PREPARATION OF POWDERS CONTAINING COLLOIDAL PARTICLES - The invention discloses a method for preparing a powder from an aqueous liquid which comprises colloidal particles. The method is based on the use of dense-phase extraction media, i.e. near-critical or supercritical fluids. The powder obtained through the method can be reconstituted with an appropriate aqueous liquid to yield a colloidal dispersion. The method is particularly useful for drying and stabilising aqueous colloidal dispersions comprising an active compound, such as a drug substance. | 06-18-2009 |
20090238797 | NICOTINE-CARRIER VACCINE FORMULATION - The present invention is in the fields of medicine, public health, vaccine and drug formulation. The invention provides composition formulations comprising a nicotine-carrier conjugate and a stabilizer, wherein said stabilizer comprises a non-reducing disaccharide and a non-ionic surfactant. The composition formulations are stable after a long time of storage at room temperature. | 09-24-2009 |
20100034823 | Crystalline anti-hTNFalpha antibodies - The present invention relates to a batch crystallization method for crystallizing an anti-hTNFalpha antibody which allows the production of said antibody on an industrial scale; antibody crystals as obtained according to said method; compositions containing said crystals as well as methods of use of said crystals and compositions. | 02-11-2010 |
20100196961 | VARIABLE TANGENTIAL FLOW FILTRATION - The current invention reports a method for concentrating an immunoglobulin solution by tangential flow filtration wherein the transmembrane pressure and the cross-flow are variable. | 08-05-2010 |
20100239654 | VESICULAR PHOSPHOLIPID GELS COMPRISING PROTEINACEOUS SUBSTANCES - The present invention relates to a pharmaceutical composition for sustained release of a pharmaceutically active compound, the composition comprising a vesicular phospholipid gel. More particularly, the invention relates to a pharmaceutical composition comprising at least one proteinaceous substance as the pharmaceutically active compound in encapsulated form, the at least one proteinaceous substance being a biologically active protein, peptide or polypeptide. Furthermore, the present invention relates to a method for the production of said pharmaceutical composition comprising dual asymmetric centrifugation and to the use of said pharmaceutical composition for immunotherapy and/or for stimulating selective tissue regeneration in the treatment of surgical defects in the course of surgical interventions. | 09-23-2010 |
20100249384 | IMMUNOGLOBULIN AGGREGATES - The current invention reports a method for concentrating an immunoglobulin solution by tangential flow filtration wherein the immunoglobulin in polymeric form can be removed after the concentration. | 09-30-2010 |
20100297214 | PERCOLATIVE DRYING FOR THE PREPARATION OF PARTICLES - The present invention relates to dry particles and methods of preparing the same, in particular to methods of producing dry particles comprising a thermally labile component such as a colloidal system or a thermally labile biopharmaceutical compound, to the use of such dry particles, and to pharmaceutical compositions comprising the same. | 11-25-2010 |
20100316696 | LIPOSOME PREPARATION BY SINGLE-PASS PROCESS - The present invention relates to a method of preparing liposomes in a single-pass mode. The method comprises the extusion of a solution or suspension through a porous device and subsequently passing said suspension or solution through a nozzle. Passing the suspension through said nozzle may result in an atomisation of the suspension or solution into droplets which might be employed in a subsequent spray-drying or spray-freezing process. | 12-16-2010 |
20110038926 | Method of producing a cationic liposomal preparation comprising a lipophilic compound - A method for producing a cationic liposomal preparation comprising a lipophilic active compound with physical and chemical stability during manufacturing, storing and reconstituting, and further a cationic liposomal preparation obtainable by this method as well as specific cationic liposomal preparations as well as pharmaceutical compositions are disclosed. | 02-17-2011 |
20110059140 | EXTRUDED ROD-SHAPED DEVICES FOR CONTROLLED RELEASE OF BIOLOGICAL SUBSTANCES TO HUMANS AND ANIMALS - The present invention relates to an extruded rod-shaped device which comprises at least one biological substance and a lipoid composition that comprises a high melting lipid or lipoid component and a low melting lipid or lipoid component. The extruded rod-shaped device according to the present invention is obtainable by extrusion of a preparation comprising the lipoid composition and the at least one biological substance, the preparation being extruded at a temperature which is at or above the melting point of the low melting lipid or lipoid component but below the melting point of the high melting lipid or lipoid component. Such an extruded rod-shaped device is capable of continuously and homogenously releasing the biological substance into the body of an animal or a human while maintaining the biological activity the biological substance and may for example be used as an implant. | 03-10-2011 |
20120087975 | Method of Producing A Cationic Liposomal Preparation Comprising A Lipophilic Compound - A method for producing a cationic liposomal preparation comprising a lipophilic active compound with physical and chemical stability during manufacturing, storing and reconstituting, and further a cationic liposomal preparation obtainable by this method as well as specific cationic liposomal preparations as well as pharmaceutical compositions are disclosed. | 04-12-2012 |
20120177704 | CRYSTALLINE ANTI-HUMAN IL-12 ANTIBODIES - The invention relates to batch crystallization methods for crystallizing an anti-hIL-12 antibody that allows the production of the antibody on an industrial scale, antibody crystals obtained according to the methods, compositions containing the crystals, and methods of using the crystals and the compositions. | 07-12-2012 |
20120219990 | PRE-FILTRATION ADJUSTMENT OF BUFFER SOLUTES - Herein is reported a tangential flow filtration method with a pre-filtration solute concentration adjustment in order to ensure a defined concentration of the components of the solution after tangential flow filtration. | 08-30-2012 |
20120231041 | Immunomodulating Nanoparticulate Composition - The present invention relates to a preferably nebulizable pharmaceutical composition comprising a pharmaceutically acceptable protein-based nanocarrier preferably in the size range 150 to 300 nm and a preventative or therapeutic amount of an active agent for use in the prevention and/or treatment of an allergic and/or inflammatory disease of the lower airways in a mammal. Preferably, the active agent is a CpG oligodeoxynucleotide (CpG-ODN), and preferably the composition exhibits a prolonged clinical effect. | 09-13-2012 |
20120251550 | Crystalline anti-hTNFalpha antibodies - The present invention relates to a batch crystallization method for crystallizing an anti-hTNFalpha antibody which allows the production of said antibody on an industrial scale; antibody crystals as obtained according to said method; compositions containing said crystals as well as methods of use of said crystals and compositions. | 10-04-2012 |
20130109056 | Immunoglobulin aggregate removal | 05-02-2013 |
20130109762 | SILK PARTICLES FOR CONTROLLED AND SUSTAINED DELIVERY OF COMPOUNDS | 05-02-2013 |
20130309309 | CRYSTALLINE ANTI-HTNFALPHA ANTIBODIES - The present invention relates to a batch crystallization method for crystallizing an anti-hTNFalpha antibody which allows the production of said antibody on an industrial scale; antibody crystals as obtained according to said method; compositions containing said crystals as well as methods of use of said crystals and compositions. | 11-21-2013 |
20140017256 | CRYSTALLINE ANTI-HUMAN IL-12 ANTIBODIES - The invention relates to batch crystallization methods for crystallizing an anti-hIL-12 antibody that allows the production of the antibody on an industrial scale, antibody crystals obtained according to the methods, compositions containing the crystals, and methods of using the crystals and the compositions. | 01-16-2014 |
20140205657 | METHOD OF PRODUCING A CATIONIC LIPOSOMAL PREPARATION COMPRISING A LIPOPHILIC COMPOUND - A method for producing a cationic liposomal preparation comprising a lipophilic active compound with physical and chemical stability during manufacturing, storing and reconstituting, and further a cationic liposomal preparation obtainable by this method as well as specific cationic liposomal preparations as well as pharmaceutical compositions are disclosed. | 07-24-2014 |
20140371292 | Method for the controlled intracellular delivery of nucleic acids - The present invention relates to a method for the controlled intracellular delivery of nucleic acid molecules into one or more target cells, in particular tumor cells, the method comprising: providing a polymeric complex formed between one or more nucleic acid molecules to be delivered and one or more cationic carrier molecules, wherein at least a part of the one or more carrier molecules in the polymeric complex are covalently attached to hydroxyalkyl starch, and wherein the hydroxyalkyl starch is shielding the polymeric complex; allowing the shielded polymeric complex to get into contact with the one or more target cells; deshielding the polymeric complex by removing the hydroxyalkyl starch; and allowing the deshielded polymeric complex to internalize into the one or more target cells. Removal of the hydroxyalkyl starch can be accomplished enzymatically by exposing the polymeric complex to amylase. The invention also concerns the use of such method for the prevention and/or treatment of a condition selected from the group consisting of cancer, immune diseases, cardiovascular diseases, neuronal diseases, infections, and inflammatory diseases. | 12-18-2014 |